Chest Medicine
JAMA Network Series: Medical Specialties and the COVID-19 Pandemic
24 Sep, 2020 | 09:45h | UTCEditorial: The COVID-19 Pandemic and the JAMA Network
See articles:
- Cardiology and COVID-19
- Dermatology and COVID-19
- Internal Medicine and COVID-19
- Nephrology and COVID-19
- Neurology and COVID-19
- Oncology and COVID-19
- Ophthalmology and COVID-19
- Otolaryngology–Head and Neck Surgery and COVID-19
- Pediatrics and COVID-19
- Psychiatry and COVID-19
- Surgery and COVID-19
- JAMA Network Open and COVID-19
- JAMA Health Forum and COVID-19
As their numbers grow, COVID-19 “long haulers” stump experts
24 Sep, 2020 | 09:33h | UTCAs Their Numbers Grow, COVID-19 “Long Haulers” Stump Experts – JAMA
Commentary on Twitter
Many #COVID19 long haulers didn’t require hospitalization, let alone ICU stays. Researchers suspect #SARSCoV2 can trigger long-lasting changes in the immune system, especially in the lungs, which may persist long after patients stop shedding the virus https://t.co/UuRr0LbLy5
— JAMA (@JAMA_current) September 24, 2020
The BMJ interview: Anthony Fauci on Covid-19
24 Sep, 2020 | 09:36h | UTCThe BMJ interview: Anthony Fauci on covid-19 – The BMJ
Commentary on Twitter
Anthony Fauci, one of the world’s most respected infectious disease experts, speaks with The BMJ’s @fgodlee about the pressures of advising the US president, the challenging nature of the new coronavirus, and how the pandemic might endhttps://t.co/4CuMFTEiKl @NIAIDNews
— The BMJ (@bmj_latest) September 23, 2020
Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection
24 Sep, 2020 | 09:32h | UTCCommentary: Simple blood test can predict severity of COVID-19 for some patients – University of Texas Health Science Center at Houston AND Routine blood test may identify patients at risk for severe COVID-19 – UPI
Commentary on Twitter
Death in #COVID19: JAMA Open
In lots of dzs RDW >14.5% robustly risk stratifies pts w/in illness. True in #COVID! Mortality w/ nl RDW 11% vs. 31% with high RDW (9% ⬆️ risk per 0.5% increase in RDW). BEST predictor next to Age!https://t.co/aZJ3p488cN#medtwitter #tipsfornewdocs pic.twitter.com/967g2HElYH— WesElyMD (@WesElyMD) September 23, 2020
Things we do for no reason: Routine coverage of anaerobes in aspiration pneumonia
24 Sep, 2020 | 09:17h | UTCSee collection: Choosing Wisely: Things We Do For No Reason – Journal of Hospital Medicine
[Preprint] Randomized trial: Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers
23 Sep, 2020 | 14:17h | UTC
Commentary on Twitter
🔥 #Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial 🔥
-1st RCT on HCQ as PrEP
-1483 HCW randomized to HCQ 1x or 2x weekly or placebo
-No difference in development of confirmed or probable COVID19 https://t.co/Gn1otqKhrW pic.twitter.com/3r0HB56h9y
— Ilan Schwartz is on🦋 (@GermHunterMD) September 21, 2020
Meta-analysis: Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections
23 Sep, 2020 | 14:24h | UTCCommentary: Studies explore asymptomatic COVID-19 cases, racial inequities – CIDRAP
COVID-19 clinical trials: Learning from exceptions in the research chaos
23 Sep, 2020 | 14:50h | UTCCOVID-19 clinical trials: learning from exceptions in the research chaos – Nature
Commentary on Twitter
Our analysis on #COVID clinical trials on Nature Medicine. Only big randomised trials can answer rapidly & reliably. Megatrials need support from regulators, funders, health services, docs. Pre-existing trial networks helpful. Collaboration key to success. https://t.co/YlalAEMR9r pic.twitter.com/wElfXfXdol
— Kari Tikkinen (@KariTikkinen) September 22, 2020
What can we expect from first-generation COVID-19 vaccines?
22 Sep, 2020 | 10:02h | UTCWhat can we expect from first-generation COVID-19 vaccines? – The Lancet
Commentary on Twitter
We need to calibrate our expectations for the 1st generation of #SARSCoV2 vaccines https://t.co/QTJbyOd9xQ @TheLancet by @gmleunghku and Malik Peiris @hkumed Pe-covid normalcy is not near. pic.twitter.com/Y15TqfoRlf
— Eric Topol (@EricTopol) September 21, 2020
Ensuring adequate palliative and hospice care during COVID-19 surges
22 Sep, 2020 | 09:57h | UTCEnsuring Adequate Palliative and Hospice Care During COVID-19 Surges – JAMA
Commentary on Twitter
An ethical approach to #pandemic surge planning requires providing for patients seeking symptom relief & comfort at the end of life. Not to do so undermines patient, family trust, emotional health, and core values of society https://t.co/P0LeYuZwzt @MatthewWynia @CUPallCare
— JAMA (@JAMA_current) September 22, 2020
Editorial: How severe COVID-19 infection is changing ARDS management
22 Sep, 2020 | 09:37h | UTCHow severe COVID-19 infection is changing ARDS management – Intensive Care Medicine
[ESMO2020 press release – Not published yet] Randomized trial: No benefit for post-operative radiotherapy in non-small-cell lung cancer
22 Sep, 2020 | 09:23h | UTCCommentary: Phase 3 Trial Results Do Not Support PORT in Resected Stage IIIAN2 NSCLC – Targeted Oncology
[Preprint] Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: An international collaborative meta-analysis of randomized trials
20 Sep, 2020 | 21:42h | UTC
Commentary on Twitter
This meta-analysis of 7,913 patients from 26 RCTs (16 unpublished) found no mortality benefit to #hydroxychloroquine or chloroquine in COVID19
Combined summary OR for all-cause mortality for HCQ 1.08, 95%CI 0.99-1.18
Confirms HCQ does not help, may harmhttps://t.co/4o9bXkOo5Q pic.twitter.com/QG1XMzN0da
— Ilan Schwartz is on🦋 (@GermHunterMD) September 19, 2020
Decreased influenza activity during the COVID-19 pandemic
20 Sep, 2020 | 21:39h | UTCCommentary: COVID-19 prevention might translate into – MedicalXpress
Severe COVID-19 infections—knowledge gained and remaining questions
20 Sep, 2020 | 21:43h | UTCSevere COVID-19 Infections—Knowledge Gained and Remaining Questions – JAMA Internal Medicine
Commentary on Twitter
Just out @JAMAInternalMed – our editorial on what we've learned about severe #Covid19 pneumonia so far and what challenges are still ahead. Honored and proud to have written this together with Carolyn Calfee and Dan Brodie. https://t.co/rmVjUWNyvM
— Lieuwe Bos – Acute Pulmonary Medicine (@Acute_Pulmo_Med) September 18, 2020
Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19
20 Sep, 2020 | 21:30h | UTC
Editorial: Convalescent plasma for Covid-19
20 Sep, 2020 | 21:29h | UTCConvalescent plasma for covid-19 – The BMJ
Commentary on Twitter
Last month the US FDA authorised the emergency use of convalescent plasma for hospital patients with covid-19. What evidence underpinned the FDA’s controversial decision? And will the authorisation make it more difficult to recruit participants for RCTS? https://t.co/PMO13J2IOq
— The BMJ (@bmj_latest) September 19, 2020
Transmission of SARS-CoV-2: A review of viral, host, and environmental factors
18 Sep, 2020 | 09:43h | UTC
Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: A narrative review
18 Sep, 2020 | 09:39h | UTC
The pooled prevalence of pulmonary embolism in patients with COVID-19
18 Sep, 2020 | 09:37h | UTCThe pooled prevalence of pulmonary embolism in patients with COVID-19 – Intensive Care Medicine
Commentary on Twitter
Pulmonary embolism in #COVID19, be careful! quantitative meta-analysis ->
pooled prevalence in pts undergoing #PE diagnosis 28%
higher pooled prevalence in pts admitted to #ICU vs those admitted to non-ICU: 19 vs 9%
Open access @yourICM #COVIDFOAM #FOAMcc https://t.co/dUqKAVoeCV pic.twitter.com/fvmQnTlv1M— Intensive Care Medicine (@yourICM) September 15, 2020
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong
18 Sep, 2020 | 09:34h | UTCClustering and superspreading potential of SARS-CoV-2 infections in Hong Kong – Nature Medicine
Commentary: Superspreaders of SARS-CoV-2 – Virology Blog
Commentaries on Twitter
Cases linked to #superspreading events are estimated to account for 80% of all local transmission of #SARSCoV2 in Hong Kong in a study with implications for public health policies. @bencowling88 @gmleunghku @SCauchemez @DillonCAdam @hkumed #quarantinehttps://t.co/tniPhKNhs5
— Nature Medicine (@NatureMedicine) September 17, 2020
We can learn a lot about superspreader events from this new @NatureMedicine paper https://t.co/ouO7CyGXQE by @DillonCAdam @bencowling88 @gmleunghku @hkumed
The Pareto 80/20 rule applied: 19% of infections were responsible for 80% of transmissions; 69% of cases did not transmit— Eric Topol (@EricTopol) September 17, 2020
Covid-19: Do many people have pre-existing immunity?
18 Sep, 2020 | 09:41h | UTCCovid-19: Do many people have pre-existing immunity? – The BMJ
Commentary on Twitter
It seemed a truth universally acknowledged that the human population had no pre-existing immunity to SARS-CoV-2, but is that actually the case? Peter Doshi explores the emerging research on immunological responseshttps://t.co/6LYRjxlWBQ
— The BMJ (@bmj_latest) September 17, 2020
Fast coronavirus tests: what they can and can’t do
17 Sep, 2020 | 09:35h | UTCFast coronavirus tests: what they can and can’t do – Nature
[Press release – not published yet] Eli Lilly reports first, promising results for an antibody against COVID-19
17 Sep, 2020 | 09:28h | UTCEli Lilly reports first, promising results for an antibody against COVID-19 – Science
Press release: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
CDC Study: Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19
17 Sep, 2020 | 09:29h | UTC
Commentary on Twitter
.@CDCMMWR report looking at almost 600 hospitalized pregnant women with #COVID19 found that pregnant women can have severe illness and poor birth outcomes, such as the mother requiring intensive care, pregnancy loss, and preterm birth. Learn more: https://t.co/g7WsFWJdDs. pic.twitter.com/Ve0dnGNTDM
— CDC (@CDCgov) September 16, 2020